The Zacks Analyst Blog Highlights: Watson Pharmaceuticals, Shire, Depomed, Comcast and Microsoft - Press Releases - NASDAQ

Last month, Watson Pharma was in another patent infringement lawsuit, when the company announced the filing of an ANDA with the FDA for a generic version of Depomed Inc. 's ( DEPO) diabetes drug, Glumetza. The drug is used as an adjunct to diet ...

Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc. - Phramalive.com

Gralise™ (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by ...

Depomed to Present at Bank of America Merrill Lynch 2012 Health Care Conference - Stockhouse

Gralise™ (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by ...

Santarus Reports First Quarter 2012 Financial Results - Seekingalpha.com

2 Other revenue included $10.3 million of GLUMETZA promotion revenue in the first quarter of 2011 Net income for the first quarter of 2012 was $0.6 million, diluted EPS was $0.01 and adjusted earnings before interest, tax, depreciation and amortization ...

Santarus, Inc: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report - new company profile report - Transworld News

The company also offers metformin hydrochloride extended release tablets under GLUMETZA brand, which acts as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Santarus distributes its products to a broad ...

Santarus Announces Presentation of UCERIS Phase III Extended Use Data at Digestive Disease Week Meeting - Marketwatch

The company's current commercial efforts are focused on GLUMETZA(R) (metformin hydrochloride extended release tablets) and CYCLOSET(R) (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic ...

Watson and Shire in Legal Battle - Zacks.com

In response, Depomed and Valeant International together filed a lawsuit against Watson Pharma in the U.S. District Court for the District of Delaware, to prevent Watson Pharma from commercializing generic Glumetza before the patents expire. We currently ...

3 Rising Biotech Stocks To Keep A Close Eye On For Trading Profits - Seekingalpha.com

2011 After starting 2012 on a strong note by doubling total revenues doubled from the prior year period thanks to a significant contribution from net sales of GLUMETZA®, higher sales of CYCLOSET® and an encouraging start of FENOGLIDE®. Gerald T.

BUYINS.NET: NILE, SSRI, ARTNA, XL, SNTS, STEC Expected To Be Down After Next Earnings Releases - TMCnet

The company commercializes CYCLOSET (bromocriptine mesylate) tablets, and focuses to commercialize GLUMETZA (metformin hydrochloride extended release tablets) that are indicated as adjuncts to diet and exercise to improve glycemic control in ...